Management

Dale Dhanoa, Ph.D.
Founder and CEO

Dr. Dale Dhanoa is the Founder, President & CEO of INVENT Pharmaceuticals. He has over 25 years of experience in executive management, R&D management, operations  and strategic partnering  from world class pharmaceutical and biotech companies. He began his career at Merck & Co. Inc. by joining Merck Research Laboratories in Rahway, NJ, USA. Prior to leading INVENT Pharmaceuticals, he was the CEO of Akaal Pharma (USA, UK and Australia), Executive Vice President (EVP) and CSO of PharmaCore, Inc., Senior Vice President (SVP) of Research and Discovery at Predix Pharmaceuticals, SVP of drug discovery at Predix Pharmaceuticals Holdings Inc. After Merck, he joined Synaptic Pharmaceuticals, a pioneering biotech company (SNAP/Nasdaq, acquired after IPO by Lundbeck A/S) in hGPCR drug discovery and development of small molecule drugs, Alanex Corporation (acquired Pre-IPO by Agouron, now Pfizer, Inc.), 3-Dimensional Pharmaceuticals (DDDP/Nasdaq, acquired post-IPO by Johnson & Johnson), PharmaCore, Inc. (acquired by Cambrex, Inc) and Predix Pharmaceuticals (M&A with a Nasdaq company).  All three biotechs namely Alanex Corp (acquired by Agouron), 3-Dimensional Pharmaceuticals, Inc.  (acquired by J&J) , and Predix Pharmaceuticals were early pioneers in developing and applying Artificial Intelligence and machine learning in drug discovery.   The drug pipelines created by and under Dr. Dhanoa's vision, leadership and direction raised significant capital that culminated in successful IPOs and M&As between private/public biopharmaceutical companies. He also established strategic partnerships with world-class Pharmaceutical corporations including Novartis, Roche Biosciences and Novo Nordisk, DuPont, Boehringer Ingelheim, Merck KGaA, BMS, J&J, Amgen, AstraZeneca and Aventis and others. Dr. Dhanoa has invented/authored over 100 US and foreign patents and publications.